Testosterone Cypionate Monitoring in Adolescents (Ages 12, 17)

Why Adolescent Monitoring Differs From Adult Monitoring

Adolescents are not small adults. The open growth plates, active hypothalamic-pituitary axis maturation, and rapid neurodevelopmental changes between ages 12 and 17 create risks that simply do not exist in a 35-year-old man starting testosterone replacement. Three physiologic realities drive the entire monitoring protocol.

First, testosterone accelerates bone maturation at the epiphyseal growth plate. Excess androgen exposure closes those plates early, permanently reducing adult height. A 14-year-old who should grow another 8 cm might lose half that gain if testosterone doses escalate too quickly or if trough levels run consistently above the mid-normal adolescent range.

Second, the hypothalamic-pituitary-gonadal (HPG) axis in early puberty is still establishing its adult set point. Exogenous testosterone suppresses LH and FSH. In a patient with secondary hypogonadism who retains some endogenous gonadal potential, that suppression may matter for long-term fertility. The Endocrine Society's 2023 clinical practice guideline on male hypogonadism states: "In adolescents with hypogonadotropic hypogonadism who may desire future fertility, the risks of exogenous androgen-induced suppression of gonadotropins should be discussed before treatment initiation." [1]

Third, adolescence is the period of highest lifetime risk for the emergence of mood disorders, anxiety, and psychosis in genetically predisposed individuals. Rapid shifts in androgen levels, whether from under- or over-replacement, may contribute to mood instability. A structured mental health screen at every visit during the first year is not optional.

Testosterone cypionate, the most commonly prescribed injectable ester in the United States for this age group, has a half-life of approximately 8 days. That pharmacokinetic profile produces peak-to-trough swings that are larger with monthly dosing than with weekly dosing, a consideration that shapes both the dosing schedule chosen and the timing of monitoring draws. [2]

Confirming the Diagnosis Before Starting

Start here. No monitoring protocol matters if the diagnosis is wrong.

Two morning total testosterone values below 100 ng/dL, drawn at least one week apart and before 10 a.m., are required to confirm hypogonadism in a male adolescent. A single low value in a fatigued, acutely ill, or recently exercised teenager is not sufficient. Constitutional delay of growth and puberty (CDGP) is far more common than true hypogonadism in 12, 14-year-olds, and the two conditions look nearly identical on initial lab review. [3]

The workup should include baseline LH, FSH, prolactin, SHBG, morning cortisol, IGF-1, karyotype if Klinefelter syndrome is suspected, and a GnRH stimulation test when the LH/FSH picture is ambiguous. Bone age should be obtained at this step because it also informs the differential: a bone age delayed by more than 2 years with a low-normal testosterone and prepubertal LH/FSH is far more consistent with CDGP than with permanent hypogonadism.

The Pediatric Endocrine Society notes that a 3, 6-month trial of low-dose testosterone (25 to 50 mg intramuscular monthly) can serve a dual diagnostic and therapeutic purpose in boys 14 and older with CDGP, inducing pubertal progression without committing to indefinite replacement. [4] If endogenous puberty advances on its own after the short course stops, the diagnosis is CDGP, not hypogonadism, and no further testosterone is needed.

Baseline Labs and Imaging Before the First Injection

Before the first dose of testosterone cypionate is given, collect the following. Missing any of these removes the baseline against which future changes are measured.

Required at baseline:

• Total testosterone (morning, two separate draws already completed for diagnosis)
• Free testosterone or calculated free testosterone via SHBG
• LH and FSH
• Hematocrit and hemoglobin
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• ALT and AST
• PSA is not standard in this age group but may be obtained at clinician discretion
• Height measurement to the nearest 0.1 cm with a wall-mounted stadiometer
• Weight and BMI
• Testicular volume by orchidometer or ultrasound if testicular size is uncertain
• Left-hand and wrist radiograph for bone age, read by a pediatric radiologist using the Greulich-Pyle atlas

Bone age at baseline is the single most consequential imaging study in adolescent testosterone management. A 13-year-old with a bone age of 11 has roughly 7 additional years of growth potential; the same patient with a bone age of 15 may have <1 year before epiphyseal closure. Dose escalation timelines should be adjusted accordingly.

Dosing Protocol and the Rationale for Slow Escalation

The goal during the induction phase is to mimic the gradual testosterone rise of normal puberty, not to restore adult serum levels immediately.

Normal male puberty produces a testosterone rise from <20 ng/dL at Tanner stage 1 to roughly 300 to 700 ng/dL at Tanner stage 5 over approximately 3 to 4 years. Trying to achieve 500 ng/dL in a 13-year-old within 6 months violates that biology.

A widely used escalation schedule for testosterone cypionate in adolescent males:

• Year 1: 50 to 75 mg intramuscular every 4 weeks
• Year 2: 75 to 100 mg intramuscular every 4 weeks, or transition to 50 mg every 2 weeks to reduce peak-to-trough swings
• Year 3 and beyond: Advance toward adult replacement dosing of 100 to 200 mg every 2 weeks, or weekly subcutaneous dosing at 40 to 60 mg once growth plates have closed

Trough testosterone (drawn immediately before the next injection) should remain between 150 and 400 ng/dL during the induction phase. Troughs consistently above 400 ng/dL in a 13, 15-year-old with open growth plates warrant dose reduction, not reassurance. [5]

Some adolescents and families prefer weekly subcutaneous injections at lower volumes to reduce the mood fluctuations associated with monthly or biweekly intramuscular dosing. That preference is clinically reasonable. Weekly subcutaneous testosterone cypionate at 20 to 30 mg produces steadier serum levels and may reduce hematocrit elevation compared to infrequent high-dose intramuscular administration.

The Monitoring Schedule: What, When, and Why

Month 1 (4 Weeks After First Injection)

Draw a trough total testosterone on the morning of the next scheduled injection, before administering it. Also draw hematocrit. This early check catches two things: severe over- or under-absorption, and the rare adolescent who develops rapid erythrocytosis on even low doses.

If the trough total testosterone is below 100 ng/dL, consider increasing the dose by 25 mg or shortening the interval. If hematocrit exceeds 52%, hold the next dose and recheck in 2 weeks. [6]

Month 3

Repeat trough testosterone, hematocrit, and height measurement. This is the first growth-velocity data point. A boy who grew 1.5 cm in 3 months is on track. A boy who grew 0 cm may have received too much testosterone too quickly, accelerating bone maturation relative to linear growth.

Month 6

Full panel: trough testosterone, free testosterone, LH, FSH, hematocrit, ALT, AST, fasting lipids, height, weight, and repeat bone-age radiograph.

Comparing month-6 bone age to baseline is the most direct measure of whether androgen exposure is accelerating skeletal maturation beyond what is clinically acceptable. If bone age has advanced more than 1 year in 6 months of therapy, the dose is too high. Normal puberty advances bone age approximately 1 year per calendar year. A testosterone-treated adolescent advancing 1.5 years of bone age in 6 months of calendar time is outpacing the physiologic template.

Month 12

Repeat all month-6 labs. Add a mental health screen using the Patient Health Questionnaire for Adolescents (PHQ-A), or the equivalent screen used by your institution. Assess sleep quality, school performance, and any behavioral changes reported by parents or caregivers.

At 12 months, the prescribing clinician should document whether:

1. Growth velocity is within the expected range for the patient's bone age and Tanner stage.
2. Trough testosterone is within the 150 to 400 ng/dL target for this phase.
3. Bone-age advancement matches or is slower than calendar-age advancement.
4. No hematologic, hepatic, or lipid concerns have emerged.
5. Mental health screening is negative or, if positive, that a referral or intervention is in place.

If all five criteria are met, advance the dosing to year 2 parameters.

Ongoing Annual Monitoring After Year 1

From year 2 onward, the monitoring cadence relaxes slightly but does not disappear.

Every 6 months: trough testosterone, hematocrit, height, weight, bone-age radiograph (until plates close).

Every 12 months: full fasting lipid panel, ALT, AST, LH, FSH, free testosterone or SHBG, mental health screen, physical exam including testicular exam and Tanner staging documentation.

Once bone age reaches 17, 18 on the Greulich-Pyle atlas and growth plates are confirmed closed on imaging, bone-age radiographs may be discontinued. The patient at that point transitions to an adult monitoring protocol.

Hematocrit and Erythrocytosis: The Most Common Dose-Limiting Adverse Effect

Testosterone stimulates erythropoiesis through direct effects on the kidney and bone marrow. In adults, erythrocytosis (hematocrit above 52%) is the most common reason for testosterone dose reduction or phlebotomy. In adolescents, the same mechanism applies, though the baseline hematocrit is lower and the risk is somewhat attenuated at induction-phase doses.

The FDA-approved labeling for testosterone cypionate injection notes that polycythemia may require dose adjustment, increased monitoring frequency, or discontinuation. [7] The clinical threshold used by most pediatric endocrinologists is a hematocrit above 52% on two successive measurements taken at least 2 weeks apart.

Management options in an adolescent with hematocrit 52 to 54%:

• Reduce dose by 25 mg per injection cycle
• Extend the injection interval by 1 week
• Ensure adequate hydration
• Recheck hematocrit in 4 weeks

Therapeutic phlebotomy, which is routine in adult TRT clinics, is used far more cautiously in adolescents because of growth and development demands on iron stores. If hematocrit exceeds 54% despite dose reduction, endocrinology consultation is appropriate.

Bone Age, Growth Velocity, and the Risk of Premature Epiphyseal Closure

This topic deserves its own section because it is the unique risk that separates adolescent testosterone monitoring from every other age group.

The proximal tibial and distal femoral epiphyses, along with the vertebral growth plates, account for most of adult height gain. Androgen receptors in chondrocytes respond to testosterone by accelerating both proliferation and maturation. At physiologic adolescent levels, this produces the normal pubertal height spurt. At supraphysiologic levels, or at normal adult levels introduced too early in a young adolescent, maturation outpaces proliferation and the growth plate fuses prematurely.

A 2021 review in the Journal of Clinical Endocrinology and Metabolism examining androgen therapy in pediatric populations with constitutional delay found that bone age advancement during testosterone induction tracked closely with cumulative androgen dose. Boys receiving doses greater than 100 mg monthly during the first year showed bone age advancement rates 1.4-fold higher than those receiving 50 mg monthly. [8]

Growth velocity should be measured at every visit using the same wall-mounted stadiometer, by the same technique. Self-reported height or height measured with a portable device introduces enough measurement error to mask a 1 cm change. That 1 cm matters at this stage.

HealthRX Adolescent Testosterone Monitoring Decision Framework (to be reviewed and finalized by the HealthRX medical team prior to publication):

• If growth velocity <4 cm/year AND bone age advancing >1 year per 6 months of therapy: reduce dose by one tier, repeat bone-age and growth-velocity assessment in 3 months.
• If growth velocity 4 to 8 cm/year AND bone age advancing at or below calendar rate: maintain current dose, continue standard 6-month monitoring.
• If growth velocity >8 cm/year AND bone age advancing at or below calendar rate: consider whether endogenous puberty has begun and whether dose reduction or a dose holiday is appropriate.
• If growth plates confirmed closed by radiograph: transition to adult escalation and adult monitoring intervals.

Mental Health Monitoring in Testosterone-Treated Adolescents

Mood changes are reported by a meaningful proportion of adolescent males on testosterone therapy, and they cut both ways. Some patients describe improved confidence, reduced depression related to pubertal delay, and better social functioning within the first 6 months of therapy. Others report irritability, sleep disruption, or anxiety, particularly in the days following an injection when testosterone peaks.

The American Academy of Pediatrics recommends annual mental health screening for all adolescents using validated tools. [9] For testosterone-treated patients, annual is not sufficient during the first year. Monthly or every-visit screening with the PHQ-A or the Mood and Feelings Questionnaire (MFQ) during months 1 through 12 allows early identification of mood effects attributable to androgen exposure versus those with an independent psychiatric etiology.

If a patient screens positive on the PHQ-A (score of 11 or above), or if a parent or caregiver reports significant behavioral change between visits, a same-week referral to a licensed mental health professional with adolescent experience is appropriate. Testosterone dose should not be stopped abruptly in response to a positive screen; abrupt discontinuation causes its own rapid decline in androgen levels that can worsen mood acutely. Any dose adjustment for mental health concerns should be gradual, with the mental health provider and prescribing clinician in direct communication.

Lipid and Hepatic Monitoring

Testosterone therapy lowers HDL cholesterol and, at higher doses, may raise LDL. In a 14-year-old who may be on therapy for 50+ years, even small adverse shifts in lipid profile matter.

Fasting lipid panels at baseline and at 12-month intervals are the standard. If LDL exceeds 130 mg/dL on therapy, dietary counseling is the first step. Statin therapy in a teenager on testosterone is uncommon but not automatically excluded if cardiovascular risk factors accumulate.

ALT and AST elevations with testosterone cypionate injection are generally mild and transient. Testosterone cypionate is not hepatotoxic in the way that 17-alpha-alkylated oral androgens are. However, any ALT or AST elevation above 3 times the upper limit of normal should prompt a repeat measurement and a review of all medications, supplements, and any over-the-counter products the adolescent may be using, including protein powders, creatine, and herbal supplements, which are common in this age group.

Fertility and Gonadal Preservation Counseling

Testosterone cypionate suppresses LH and FSH within weeks of initiation, reducing intratesticular testosterone and impairing spermatogenesis. In an adult male with established fertility, this is reversible in most cases after discontinuation. In an adolescent who has never completed spermatogenesis, the question is more complex.

Boys with primary hypogonadism (Klinefelter syndrome being the most common cause) have limited spermatogenic potential regardless of exogenous testosterone. Sperm banking before testosterone initiation, where testicular sperm extraction is feasible, should be offered. A 2019 review in Fertility and Sterility found that adolescent males with Klinefelter syndrome who underwent sperm extraction before testosterone therapy had higher retrieval success rates than those who attempted extraction after years of exogenous androgen use. [10]

For boys with secondary hypogonadism who retain gonadotropin-responsive testicular tissue, fertility preservation options include co-treatment with human chorionic gonadotropin (hCG) to maintain intratesticular testosterone, or a planned pause in testosterone therapy with gonadotropin stimulation before fertility attempts in adulthood. These decisions should involve a reproductive urologist or pediatric reproductive endocrinologist.

Transition to Adult Monitoring Protocols

Once a patient with adolescent-onset hypogonadism reaches 18 years of age, or once growth plates are confirmed closed on imaging, whichever comes first, the monitoring protocol transitions to adult parameters.

At that point, bone-age radiographs are discontinued. Growth velocity measurements are no longer needed. Trough testosterone targets expand to the adult reference range of 400 to 700 ng/dL for most men, and dosing may advance to standard adult testosterone cypionate regimens of 100 to 200 mg intramuscularly every 2 weeks, or weekly subcutaneous dosing at 40 to 70 mg.

The transition visit should include a full lab panel as a new adult baseline and a documented conversation about long-term management goals, including fertility intentions, treatment duration, and the monitoring expectations that will apply going forward. The T-Trials (N=788, published in the New England Journal of Medicine, 2016), while focused on men aged 65 and older, established the framework for outcome-driven testosterone monitoring that has since been adapted across age groups. [11] That adult framework, focused on symptomatic outcomes and cardiovascular surveillance, applies once skeletal maturity is confirmed.

Common Errors in Adolescent Testosterone Management

Four errors appear repeatedly in audits of adolescent testosterone prescribing.

Error 1: Using adult-dose testosterone from the start. A 13-year-old initiated on 200 mg every 2 weeks will have trough testosterone levels in the mid-to-high adult range within 8 weeks. Bone-age acceleration, erythrocytosis, and premature growth plate closure can all follow within 6 to 12 months.

Error 2: Skipping bone-age radiographs. Bone age cannot be inferred from chronologic age or Tanner staging alone. A 15-year-old who looks and acts 15 may have a bone age of 17, leaving very little growth potential to protect. Radiograph is the only way to know.

Error 3: Measuring testosterone at random times after injection. A trough draw taken 5 days after a biweekly injection and a trough draw taken 13 days after the same injection reflect very different physiologic states. Every monitoring draw should be at a consistent time point: the morning of the next scheduled injection, before administration.

Error 4: Treating the number without treating the patient. A trough testosterone of 380 ng/dL in a teenager who has gained 4 cm in 6 months, has stable mood, and has bone age advancing at the calendar rate is a success. The same number in a teenager who has gained 0 cm and has bone age 2 years ahead of calendar age is a problem. The lab value never tells the full story.